Navigation Links
MannKind Agrees with Pfizer on the Purchase of Frankfurt Insulin Manufacturing Plant
Date:3/9/2009

obtain an immediate supply of insulin and the ability to supply our insulin needs for the future, even if we are unable to acquire the facility itself. We are pleased with this opportunity to secure our insulin supply, which brings AFRESA one step closer to commercial readiness."

Additional information about this transaction is available in a Current Report on Form 8-K filed by MannKind with the Securities and Exchange Commission earlier today.

About AFRESA(R)

AFRESA is an ultra rapid acting insulin product that has completed Phase 3 trials. The pharmacokinetic profile of AFRESA sets it apart from all other insulin products. The large surface area of the lung provides unique access to the circulatory system. The pH-sensitive AFRESA particles immediately dissolve upon contact with the lung surface, releasing insulin monomers that rapidly enter the bloodstream. It achieves peak insulin levels within 12-14 minutes of administration, effectively mimicking the release of meal-time insulin observed in healthy individuals, but which is absent from patients with diabetes.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its pipeline includes AFRESA, which has completed Phase 3 clinical trials, and MKC253, which is currently in phase 1 clinical trials. Both of these investigational products are being evaluated for their safety and efficacy in the treatment of diabetes. MannKind maintains a website at http://www.mannkindcorp.com to which MannKind regularly posts copies of its press release as well as additional information about MannKind. Interested persons can subscri
'/>"/>

SOURCE MannKind Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on February 17, 2009
2. MannKind to Present at the 11th Annual Biotechnology Industry Organization BIO CEO & Investor Conference
3. SemBioSys receives US$2.5 million from option agreement with MannKind for plant-produced insulin
4. MannKind to Present at the Piper Jaffray 20th Annual Health Care Conference
5. MannKind to Present at the Rodman & Renshaw Annual Global Investment Conference
6. MannKind Corporation to Hold Third Quarter Financial Results Conference Call on November 5, 2008
7. MannKind Unveils Proposed Trade Name at Dedication of Danbury Manufacturing Facility
8. MannKind to Present at the UBS Global Life Sciences Conference
9. MannKind Corporation Reports Second Quarter Financial Results
10. MannKind Corporation to Hold Second Quarter Financial Results Conference Call on August 11, 2008
11. MannKind to Present at Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... 2014 Called the NOAH Protocol, ... several types of pediatric brain cancer. The implications ... over 30 years of research and development. Amber ... that one mom's determination can make a difference. ... trick-or-treating, and it’s only fitting that we’ve received ...
(Date:10/27/2014)... , Oct. 27, 2014 Pressure ... a worldwide leader in the development and sale ... life sciences research market, today announced that Professor ... a novel, accurate, highly reproducible, and robust method ... routine high-throughput protein analysis on small needle biopsy ...
(Date:10/27/2014)... Investor-Edge has initiated coverage on ... NBIX ), Insmed Inc. (NASDAQ: INSM ), ... Corporation (NASDAQ: DYAX ), and Oncothyreon Inc. ... be accessed at: http://investor-edge.com/register . On ... 4,483.72, up 0.69%, the Dow Jones Industrial Average advanced ...
(Date:10/26/2014)... The report "Protective Coatings Market by Resin Type, by ... to 2019", defines and segments the global protective coatings ... value generated. The protective coatings consumption is projected to ... by 2019, at a CAGR of 9.52% during the ... 22 figures spread through 219 slides and in-depth TOC ...
Breaking Biology Technology:FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 2FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 3Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 2Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 3Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 4Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 5Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 2Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 3Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 4Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 5Protective Coatings Market Poised to Reach $18,431.8 Million by 2019 - Report by MarketsandMarkets 2Protective Coatings Market Poised to Reach $18,431.8 Million by 2019 - Report by MarketsandMarkets 3Protective Coatings Market Poised to Reach $18,431.8 Million by 2019 - Report by MarketsandMarkets 4
... February 5, SAN DIEGO, Jan. 24 Neurocrine ... Company will report its fourth,quarter and year-end 2007 financial ... 2008. Neurocrine will then host a live conference,call and ... Company,update Tuesday afternoon, February 5, 2008 at 5:00 p.m. ...
... Jan. 24 Biomatrica, the biostability company,that offers ... has introduced RNAstable(TM) for preserving RNA at room,temperature, ... Interest in RNA has skyrocketed over the ... silencer and in gene expression studies. However, RNA ...
... Jan. 24 Aton Pharma, Inc., ... that it has,launched an expanded, comprehensive ... and patient education resources, for the,dry ... Lacrisert is a unique preservative-free, once-daily*, ...
Cached Biology Technology:Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2007 Financial Results 2Biomatrica's RNAstable(TM) Stabilizes RNA at Room Temperature 2Biomatrica's RNAstable(TM) Stabilizes RNA at Room Temperature 3Aton Pharma Introduces Expanded Distribution of Lacrisert(R) (hydroxypropyl cellulose ophthalmic insert) at Hawaiian Eye 2Aton Pharma Introduces Expanded Distribution of Lacrisert(R) (hydroxypropyl cellulose ophthalmic insert) at Hawaiian Eye 3
(Date:10/29/2014)... research by the international Cancer Genomics of the ... connection between kidney cancer and exposure to aristolochic ... findings, published in Nature Communications , have ... kills more than 140,000 people every year, and ... dramatically. CAGEKID, part of the International Cancer Genome ...
(Date:10/28/2014)... the tragic realities of cancer is that the ... and their effectiveness varies unpredictably from patient to ... to change this reality by rapidly assessing how ... individual,s cancer before chemotherapy begins. , A team ... Assistant Professor Melissa Skala has developed the technique, ...
(Date:10/28/2014)... from North America, Europe and China have published a ... of Sciences that reveals important details about key ... planet., From strange and exotic algae, mosses, ferns, trees ... grains and vegetables we eat and the ornamental plants ... over a billion years of history., "Our study generated ...
Breaking Biology News(10 mins):Kidney cancer in Central Europe 2Improving breast cancer chemo by testing patient's tumors in a dish 2Improving breast cancer chemo by testing patient's tumors in a dish 3New study uses DNA sequences to look back in time at key events in plant evolution 2New study uses DNA sequences to look back in time at key events in plant evolution 3
... An entire group of millipedes previously unknown in ... shelves. Hundreds of tiny specimens of the widespread tropical family ... showing that native pyrgodesmids are not only widespread ... and diverse. The study has been published in the open ...
... 2012For many diabetics, monitoring their condition involves much more ... insulin injections. It also entails carefully monitoring the ongoing ... An innovative new optical diagnostic tool created by Columbia ... (OSA) open-access journal Biomedical Optics Express may ...
... of Leicester medical scientists have secured funding for a ... into children,s breathing. The team of researchers working ... Exhalyzer-D, a highly-specialised device made in Switzerland. ... grants from Midlands Asthma and Allergy Research Association (MAARA) ...
Cached Biology News:Millipede family added to Australian fauna 2Shedding new light on one of diabetes' most dangerous complications 2New equipment is breath of fresh air for children's lung researchers 2